Copyright Reports & Markets. All rights reserved.

Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Aloxi (Palonosetron)
    • 1.2.3 Kytril (Granisetron)
    • 1.2.4 Emend (Aprepitant)
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Acute Nausea and Vomitting Treatment
    • 1.3.3 Delayed Nausea and Vomitting Treatment
    • 1.3.4 Anticipatory Nausea and Vomitting Treatment
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Perspective (2016-2027)
  • 2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Regions
    • 2.2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Share by Regions (2016-2021)
    • 2.2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Regions (2022-2027)
  • 2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Dynamic
    • 2.3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Trends
    • 2.3.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
    • 2.3.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
    • 2.3.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue
    • 3.1.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue (2016-2021)
    • 3.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Players (2016-2021)
  • 3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue
  • 3.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio
    • 3.4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2020
  • 3.5 Chemotheraphy-induced Nausea and Vomitting Treatment Key Players Head office and Area Served
  • 3.6 Key Players Chemotheraphy-induced Nausea and Vomitting Treatment Product Solution and Service
  • 3.7 Date of Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Type

  • 4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2016-2021)
  • 4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2022-2027)

5 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Application

  • 5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2016-2021)
  • 5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 6.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 6.2.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 6.2.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 6.2.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 6.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 6.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 6.3.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 6.3.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 6.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
    • 6.4.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
    • 6.4.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 7.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 7.2.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 7.2.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 7.2.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 7.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 7.3.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 7.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 7.3.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 7.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
    • 7.4.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
    • 7.4.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 8.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 8.2.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 8.3.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region
    • 8.4.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 9.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 9.2.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 9.2.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 9.2.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 9.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 9.3.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 9.3.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 9.3.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 9.4 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
    • 9.4.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
    • 9.4.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
  • 10.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
    • 10.2.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
    • 10.3.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
    • 10.4.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 GlaxoSmithKline
    • 11.1.1 GlaxoSmithKline Company Details
    • 11.1.2 GlaxoSmithKline Business Overview
    • 11.1.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.1.4 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.1.5 GlaxoSmithKline Recent Development
  • 11.2 Helsinn
    • 11.2.1 Helsinn Company Details
    • 11.2.2 Helsinn Business Overview
    • 11.2.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.2.4 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.2.5 Helsinn Recent Development
  • 11.3 Heron Therapeutics
    • 11.3.1 Heron Therapeutics Company Details
    • 11.3.2 Heron Therapeutics Business Overview
    • 11.3.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.3.4 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.3.5 Heron Therapeutics Recent Development
  • 11.4 Merck & Co
    • 11.4.1 Merck & Co Company Details
    • 11.4.2 Merck & Co Business Overview
    • 11.4.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.4.4 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.4.5 Merck & Co Recent Development
  • 11.5 Tesaro
    • 11.5.1 Tesaro Company Details
    • 11.5.2 Tesaro Business Overview
    • 11.5.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.5.4 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.5.5 Tesaro Recent Development
  • 11.6 Acacia Pharma
    • 11.6.1 Acacia Pharma Company Details
    • 11.6.2 Acacia Pharma Business Overview
    • 11.6.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.6.4 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.6.5 Acacia Pharma Recent Development
  • 11.7 Aphios
    • 11.7.1 Aphios Company Details
    • 11.7.2 Aphios Business Overview
    • 11.7.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.7.4 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.7.5 Aphios Recent Development
  • 11.8 Barr Laboratories
    • 11.8.1 Barr Laboratories Company Details
    • 11.8.2 Barr Laboratories Business Overview
    • 11.8.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.8.4 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.8.5 Barr Laboratories Recent Development
  • 11.9 Baxter Healthcare
    • 11.9.1 Baxter Healthcare Company Details
    • 11.9.2 Baxter Healthcare Business Overview
    • 11.9.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.9.4 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.9.5 Baxter Healthcare Recent Development
  • 11.10 Eisai
    • 11.10.1 Eisai Company Details
    • 11.10.2 Eisai Business Overview
    • 11.10.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.10.4 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.10.5 Eisai Recent Development
  • 11.11 Especificos Stendhal
    • 11.11.1 Especificos Stendhal Company Details
    • 11.11.2 Especificos Stendhal Business Overview
    • 11.11.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.11.4 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.11.5 Especificos Stendhal Recent Development
  • 11.12 F.Hoffmann La Roche
    • 11.12.1 F.Hoffmann La Roche Company Details
    • 11.12.2 F.Hoffmann La Roche Business Overview
    • 11.12.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.12.4 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.12.5 F.Hoffmann La Roche Recent Development
  • 11.13 Mundipharma
    • 11.13.1 Mundipharma Company Details
    • 11.13.2 Mundipharma Business Overview
    • 11.13.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.13.4 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.13.5 Mundipharma Recent Development
  • 11.14 Mylan Pharmaceuticals
    • 11.14.1 Mylan Pharmaceuticals Company Details
    • 11.14.2 Mylan Pharmaceuticals Business Overview
    • 11.14.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.14.4 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.14.5 Mylan Pharmaceuticals Recent Development
  • 11.15 OPKO Health
    • 11.15.1 OPKO Health Company Details
    • 11.15.2 OPKO Health Business Overview
    • 11.15.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.15.4 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.15.5 OPKO Health Recent Development
  • 11.16 Orchid Healthcare
    • 11.16.1 Orchid Healthcare Company Details
    • 11.16.2 Orchid Healthcare Business Overview
    • 11.16.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
    • 11.16.4 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
    • 11.16.5 Orchid Healthcare Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Chemotheraphy-induced Nausea and Vomitting Treatment Scope and Market Size
    Chemotheraphy-induced Nausea and Vomitting Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotheraphy-induced Nausea and Vomitting Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Aloxi (Palonosetron)
    Kytril (Granisetron)
    Emend (Aprepitant)
    Others

    Segment by Application
    Acute Nausea and Vomitting Treatment
    Delayed Nausea and Vomitting Treatment
    Anticipatory Nausea and Vomitting Treatment

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    GlaxoSmithKline
    Helsinn
    Heron Therapeutics
    Merck & Co
    Tesaro
    Acacia Pharma
    Aphios
    Barr Laboratories
    Baxter Healthcare
    Eisai
    Especificos Stendhal
    F.Hoffmann La Roche
    Mundipharma
    Mylan Pharmaceuticals
    OPKO Health
    Orchid Healthcare

    Buy now